Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Relapsed/Refractory Multiple Myeloma
NCT05976555Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of B2ARM in multiple myeloma (MM) (5 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Number of Adverse Events at Day 28. Started May 2026; status: recruiting.
02
Drugs
B2ARM
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05976555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976555.